On-Demand CE for Nurse Practitioners

Earn CME on your time and at your own pace with these on-demand activities

Attack Prevention in Hereditary Angioedema: Strategies for Early Diagnosis, Treatment, and Prophylaxis

CE Information
0.5 CE credits (0.2 pharmacology)
Completion Time
30 minutes
Available Until
June 15, 2024
Posted By
Prime CE
Prime CE Prime CE
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.


Acute Care
Allergy/Immunology and Dermatology
Clinical Topics
Allergies and Dermatologic Disease

Intended Audience: Allergists, immunologists, emergency medicine physicians, dermatologists, primary care physicians, pediatricians, geneticists, and their care teams (NPs, PAs, nurses, pharmacists) working within community, academic, and system practices

Hereditary angioedema (HAE), a rare genetic disorder characterized by debilitating attacks of severe swelling, is dangerous and highly disruptive to the daily lives of those affected. Through early identification and application of prophylactic treatments, patients can achieve more attack-free days.

Tune in to this insightful presentation to hear expert guidance on accurate diagnosis, the evolving therapeutic landscape, and individualized management plans for patients with HAE. Following the activity, download a guide covering the latest diagnostic and treatment strategies for point-of-care reference.

This activity is delivered in partnership with the Allergy & Asthma Network.

Learning Objectives

  • Apply guideline-directed diagnostic screening and genetic testing for hereditary angioedema (HAE) across pediatric and adult populations to facilitate prompt diagnosis
  • Describe the clinical presentation of HAE and triggers for attacks with a focus on disease differentiation
  • Develop individualized management plans that integrate patient- and disease-specific factors into personalized treatment decisions
  • Differentiate current and emerging treatments based on the latest clinical safety and efficacy data, mechanism of action, indication, and route and frequency of administration
  • Implement strategies for interprofessional collaboration throughout the continuum of care for HAE


Paula J Busse
Paula J Busse MD

Department of Medicine
Division of Clinical Immunology
The Mount Sinai Hospital
New York, NY

Paula J. Busse MD is a Professor at the Icahn School of Medicine at Mount Sinai. She received her undergraduate degree from Wellesley College, her medical degree from the University of Rochester, and completed her medical residency training in Internal Medicine, a Clinical Research Training Program and post-doctorate training in Allergy and Immunology at Mount Sinai. Her research interests include asthma in older patients and treatment of Hereditary Angioedema. She has received NIH funding to study the impact of depression on asthma and inflammation in older adults. She is also the PI of the Childhood Asthma in Urban Settings asthma (CAUSE) network site at Mount Sinai. She has been active in the AAAAI and served as a member of the Board of Directors. Dr. Busse has conducted over 20 clinical research trials on angioedema and urticaria and has been elected to the medical advisory board for the US Hereditary Angioedema Association. She is the first author on the US guidelines for treatment of HAE.

CE Information

This activity offers 0.5 CE credits (0.2 pharmacology) to attendees.

Nurse Practitioner Accreditation Statement

PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.5 contact hour (which includes 0.2 hour of pharmacology).


*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

  • Paula J Busse, MD (Speaker)
    Advisory Board or Panel  Biocryst, Kalvista, Takeda
    Consultant  Biomarin, CSL Behring, CVS, Novartis, Regeneron
    Other Financial or Material Support (royalties, patents, etc.)  American Academy of CME, Clinical Viewpoints, Medscape

The following individuals have no relevant financial relationships with ineligible companies to disclose:

  • Richa Bhattarai, MD (Reviewer)
  • Abimbola Farinde, PhD, PharmD (Planner)
  • Lisa Wakefield, MSN, APRN, FNP-BC (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.

Ready to start this activity?

Login required. You will be redirected to an external website to register for and complete this activity.

Log in and start activity